Will the FDA approve any psychedelic substance for medical use this year?
6.0 ptn (24u)Health & MedicineOne-Off3mnd
KalshiBeschikbaarheid controlerenKYC vereist2% kostenGeverifieerde afwikkelingsgegevensRedelijk gekalibreerdHuidige impliciete kans
Nee 68%
Marktkwaliteit
64 / 100
Gemiddelde kwaliteit24u volume
€ 72,6
Liquiditeit
€ 77,1K
Hoge liquiditeitBied / Laat
29.0% / 33.0%
Spread
4.0 pt
Gematigde spreadMarktdata
Bijgewerkt 9 minuten geleden
17 jul 25, 14:00 UTC1 jan 27, 04:59 UTC
Trends
Gerelateerde Markten
Gerelateerde vragen voor context, geen vergelijking van gelijkwaardige contracten.
Will the FDA approve a psychedelic-assisted therapy for a mental disorder by 2027?
Manifold MarketsWhen will the FDA approve Compass Pathways' COMP360 Psilocybin?
Kalshi[ACX 2026] Will the FDA approve a psilocybin treatment during 2026?
Manifold MarketsWill the FDA approve MDMA for PTSD?
KalshiWill the FDA approve a psilocybin treatment during 2026?
FutuurWill the FDA approve intismeran autogene (V940/mRNA-4157)?
KalshiRegels
If the FDA approves any psychedelic substance for medical use for marketing before Jan 1, 2027, then the market resolves to Yes.
- Psychedelic drugs include: LSD, Psilocybin, DMT, Mescaline, MDMA, MDA, PCP, DXM, Ibogaine, Salvia divinorum, 2C family, and Ayahuasca.
- Important information: For purposes of this Contract:
- The listed substances are illustrative, not exhaustive.
- Approval of any other substance commonly recognized in scientific or FDA documentation as a psychedelic, hallucinogen, or entactogen (for example, psilocin, 5-MeO-DMT, methylone, or 2C-, DOx-, or NBOMe-family compounds) may also satisfy the Payout Criterion.
- "Approval for medical use" means an FDA approval letter for an NDA or BLA authorizing marketing of a drug or biologic for human medical use in the United States, where a listed (or otherwise qualifying) psychedelic substance is an active pharmaceutical ingredient of the approved product.
Open markten
Health & Medicine
POLYMARKETHantavirus pandemic in 2026?
- No97%
- Yes3%
- Totaal volume
- € 15,6 mln.
- 24u volume
- € 18K
POLYMARKETNew pandemic in 2026?
- No94.1%
- Yes5.9%
- Totaal volume
- € 920,1K
- 24u volume
- € 4K
KALSHIMedtronic cardiovascular growth in Q2
- Above 8%92%
- Above 9%81%
- Above 11.5%53%
+6 extra uitkomsten
- Totaal volume
- € 2,6K
- 24u volume
- € 2,6K
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 4000+1.0pt98%
- Above 6000+2.0pt61%
+2 extra uitkomsten
- Totaal volume
- € 868,1K
POLYMARKETMeasles cases in U.S. in 2026?
- ↑3.5k100%
- ↑500+0.1pt100%
- ↑1k+0.1pt100%
+9 extra uitkomsten
KALSHIPandemic in 2026?
- No95%
- Yes5%
- Totaal volume
- € 612,7K
- 24u volume
- € 1,2K
- When will Beam Therapeutics submit a BLA for Risto-cel?
- Which countries will report an Ebola disease case before October?
- What will RFK say during RNC Midterm Convention?
- When will the FDA approve Intellia Therapeutics' lonvo-z?
- Will the FDA approve retatrutide?
- When will Compass Pathways submit a NDA for COMP360 psilocybin?
- Measles cases in U.S. by September 30?
- Will WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- How many West Nile neuroinvasive disease cases will be reported among New York City residents in 2026?
Veelgestelde vragen
- Wat zijn de huidige kansen voor Will the FDA approve any psychedelic substance for medical use this year??
- Kalshi prijst No op 68% per 10 september 2026.
- Wanneer wordt Will the FDA approve any psychedelic substance for medical use this year? afgewikkeld?
- Will the FDA approve any psychedelic substance for medical use this year? wordt naar verwachting op 1 januari 2027 afgewikkeld.
- Hoe wordt Will the FDA approve any psychedelic substance for medical use this year? afgewikkeld?
- Kalshi wikkelt deze markt als volgt af: If the FDA approves any psychedelic substance for medical use for marketing before Jan 1, 2027, then the market resolves to Yes.